Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Medtronic
Julphar
Boehringer Ingelheim
McKinsey
Fuji

Generated: August 17, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,450,377

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,450,377
Title:1-adamantyl chalcones for the treatment of proliferative disorders
Abstract: The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I], ##STR00001## wherein the substituents are as defined in the specification.
Inventor(s): Anderson; Gloria L. (Atlanta, GA), Kaimari; Tawfeq Abdul-Raheem (Kennesaw, GA)
Assignee:
Application Number:13/224,829
Patent Claims:1. A compound of the formula: ##STR00027## wherein R.sub.1 is Ad- or Ad-(L1)n-, wherein n is 0 or 1, Ad is adamantyl, and L1 is a linking group selected from the group consisting of C1-6 alkylene, C1-6 cycloalkylene, and C1-6 arylene; Y is H; and R.sub.2 is CY1=CHR3, wherein Y1 is H, C1-6 alkyl, aryl, or halo; and R3 is aryl, aryl optionally substituted by X, or HET; X is hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, pyrrolidinyl, piperadinyl, morpholinyl, piperazinyl, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano or a phosphorus containing group; and HET is optionally substituted pyrrolidinyl, piperadinyl, morpholinyl, piperazinyl, pyrrolyl, pyridinyl, and pyridazinyl, quinolinyl, or thiophenyl, and wherein the substitutuent is X; or a pharmaceutically acceptable salt or derivative thereof.

2. The compound according to claim 1, having the formula: ##STR00028## wherein R.sub.1 is Ad- or Ad-(L1)n-, wherein n is 0 or 1, Ad is adamantyl, and L1 is a linking group selected from the group consisting of C1-6 alkylene, C1-6 cycloalkylene, and C1-6 arylene; Y is H; R.sub.2 is CY1=CHR3, wherein Y1 is H, C1-6 alkyl, aryl, or halo; R3 is aryl, or aryl optionally substituted by X; and X is hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, pyrrolidinyl, piperadinyl, morpholinyl, piperazinyl, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano or a phosphorus containing group; or a pharmaceutically acceptable salt or derivative thereof.

3. The compound according to claim 1 having the formula: ##STR00029## wherein Y is H, C1-6 alkyl, aryl, or halo; and X is hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, pyrrolidinyl, piperadinyl, morpholinyl, piperazinyl, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano or a phosphorus containing group; or a pharmaceutically acceptable salt or derivative thereof.

4. The compound according to claim 1 having the formula: ##STR00030## wherein X is H or OCH.sub.3, and Y is H, CH.sub.3 or Cl.

5. A pharmaceutical composition comprising an anti-proliferative effective amount of a compound of claim 1 having the formula: ##STR00031## wherein R.sub.1 is Ad- or Ad-(L1)n-, wherein n is 0 or 1, Ad is adamantyl, and L1 is a linking group selected from the group consisting of C1-6 alkylene, C1-6 cycloalkylene, and C1-6 arylene; Y is H; R.sub.2 is CY1=CHR3, wherein Y1 is H, C1-6 alkyl, aryl, or halo; R3 is aryl, or aryl optionally substituted by X; and X is hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, pyrrolidinyl, piperadinyl, morpholinyl, piperazinyl, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano or a phosphorus containing group; or a pharmaceutically acceptable salt or derivative thereof, in combination with a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising an anti-proliferative effective amount of a compound of claim 1 having the formula: ##STR00032## wherein Y is H, C1-6 alkyl, aryl, or halo; and X is hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, pyrrolidinyl, piperadinyl, morpholinyl, piperazinyl, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano or a phosphorus containing group; or a pharmaceutically acceptable salt or derivative thereof, in combination with a pharmaceutically acceptable carrier.

7. A method for the treatment of breast cancer comprising administering to a host in need of such treatment an anti-proliferative effective amount of a compound according to claim 1 having the formula: ##STR00033## wherein R.sub.1 is Ad- or Ad-(L1)n-, wherein n is 0 or 1, Ad is adamantyl, and L1 is a linking group selected from the group consisting of C1-6 alkylene, C1-6 cycloalkylene, and C1-6 arylene; Y is H; and R.sub.2 is CH.dbd.CHR3, wherein R.sub.3 is aryl, aryl optionally substituted by X, and X is hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, pyrrolidinyl, piperadinyl, morpholinyl, piperazinyl, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano or a phosphorus containing group; or a pharmaceutically acceptable salt or derivative thereof in combination with at least one other chemotherapeutic agent selected from the group consisting of tamoxifen, toremifene, idoxifene, droloxifene, TAT-59, LY117018, raloxifene, genistein, doxyrubicin, Taxol, Taxotere, aredia, arimidex, navilbine, busulfan, cisplatin, cyclophosphamide (Cytoxan), dacarbazine, ifosfamide, mechlorethamine (Mustargen), melphalan, carmustine, lomustine, 5-fluorouracil, methotrexate, gemcitabine, cytarabine (Ara-C), fludarabine, bleomycin, dactinomycin, daunorubicin, idarubicin, paclitaxel, docetaxel, etoposide, vinblastine, vincristine, vinorelbine, prednisone, dexamethasone, and herceptin, optionally in combination with a pharmaceutically acceptable carrier.

8. A method for the treatment of breast cancer comprising administering to a host in need of such treatment an effective amount of a compound according to claim 1 having the formula: ##STR00034## wherein R.sub.2 is CH.dbd.CHR3, wherein R3 is aryl, aryl optionally substituted by X, wherein X is hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, pyrrolidinyl, piperadinyl, morpholinyl, piperazinyl, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano or a phosphorus containing group; or a pharmaceutically acceptable salt or derivative thereof in combination with at least one other chemotherapeutic agent selected from the group consisting of tamoxifen, toremifene, idoxifene, droloxifene, TAT-59, LY117018, raloxifene, genistein, doxyrubicin, Taxol, Taxotere, aredia, arimidex, navilbine, busulfan, cisplatin, cyclophosphamide (Cytoxan), dacarbazine, ifosfamide, mechlorethamine (Mustargen), melphalan, carmustine, lomustine, 5-fluorouracil, methotrexate, gemcitabine, cytarabine (Ara-C), fludarabine, bleomycin, dactinomycin, daunorubicin, idarubicin, paclitaxel, docetaxel, etoposide, vinblastine, vincristine, vinorelbine, prednisone, dexamethasone, and herceptin, optionally in combination with a pharmaceutically acceptable carrier.

9. A method for the treatment of breast cancer comprising administering to a host in need of such treatment an effective amount of a compound according to claim 1 having the formula: ##STR00035## wherein X is H or OCH.sub.3, and Y is H, CH.sub.3 or Cl; or a pharmaceutically acceptable salt or derivative thereof in combination with at least one other chemotherapeutic agent selected from the group consisting of tamoxifen, toremifene, idoxifene, droloxifene, TAT-59, LY117018, raloxifene, genistein, doxyrubicin, Taxol, Taxotere, aredia, arimidex, navilbine, busulfan, cisplatin, cyclophosphamide (Cytoxan), dacarbazine, ifosfamide, mechlorethamine (Mustargen), melphalan, carmustine, lomustine, 5-fluorouracil, methotrexate, gemcitabine, cytarabine (Ara-C), fludarabine, bleomycin, dactinomycin, daunorubicin, idarubicin, paclitaxel, docetaxel, etoposide, vinblastine, vincristine, vinorelbine, prednisone, dexamethasone, and herceptin, optionally in combination with a pharmaceutically acceptable carrier.

Details for Patent 8,450,377

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial 2038-11-13 RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKinsey
Julphar
US Army
Accenture
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.